Bioxcel Therapeutics Stock Today
| BTAI Stock | USD 0.41 0.04 8.89% |
Performance0 of 100
| Odds Of DistressOver 84
|
BioXcel Therapeutics is trading at 0.41 as of the 30th of November 2024. This is a 8.89 percent decrease since the beginning of the trading day. The stock's open price was 0.45. BioXcel Therapeutics has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Equity ratings for BioXcel Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 1st of September 2024 and ending today, the 30th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 8th of March 2018 | Category Healthcare | Classification Health Care |
BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company was incorporated in 2017 and is headquartered in New Haven, Connecticut. The company has 48.35 M outstanding shares of which 624.14 K shares are currently shorted by private and institutional investors with about 0.93 trading days to cover. More on BioXcel Therapeutics
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
BioXcel Stock Highlights
| CEO | Vimal Mehta | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsBioXcel Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand BioXcel Therapeutics' financial leverage. It provides some insight into what part of BioXcel Therapeutics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
BioXcel Therapeutics (BTAI) is traded on NASDAQ Exchange in USA. It is located in 555 Long Wharf Drive, New Haven, CT, United States, 06511 and employs 74 people. BioXcel Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 19.76 M. BioXcel Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 48.35 M outstanding shares of which 624.14 K shares are currently shorted by private and institutional investors with about 0.93 trading days to cover.
BioXcel Therapeutics currently holds about 233.45 M in cash with (155.01 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.33, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check BioXcel Therapeutics Probability Of Bankruptcy
Ownership AllocationBioXcel Therapeutics holds a total of 48.35 Million outstanding shares. BioXcel Therapeutics retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check BioXcel Ownership Details
BioXcel Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Goldman Sachs Group Inc | 2024-06-30 | 99 K | |
| Bank Of America Corp | 2024-06-30 | 73.4 K | |
| Virtu Financial Llc | 2024-06-30 | 57.3 K | |
| Hrt Financial Llc | 2024-06-30 | 53 K | |
| Ubs Group Ag | 2024-06-30 | 52.5 K | |
| Arete Wealth Advisors, Llc | 2024-06-30 | 43.5 K | |
| Northern Trust Corp | 2024-09-30 | 40.7 K | |
| Hennion & Walsh Asset Management Inc | 2024-09-30 | 40.1 K | |
| Diversify Wealth Management, Llc | 2024-06-30 | 40 K | |
| Vanguard Group Inc | 2024-09-30 | 1.2 M | |
| Blackrock Inc | 2024-06-30 | 440.7 K |
BioXcel Therapeutics Historical Income Statement
BioXcel Stock Against Markets
BioXcel Therapeutics Corporate Management
| Frank Yocca | Chief Scientific Officer | Profile | |
| Mary Coleman | VP Relations | Profile | |
| Javier Rodriguez | Chief VP | Profile | |
| Cedric Burg | VP Management | Profile | |
| Robert Scala | Vice Planning | Profile | |
| Chetan Lathia | Clinical Medicine | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioXcel Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For more detail on how to invest in BioXcel Stock please use our How to Invest in BioXcel Therapeutics guide.You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BioXcel Therapeutics. If investors know BioXcel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BioXcel Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.04) | Revenue Per Share 0.074 | Quarterly Revenue Growth 1.416 | Return On Assets (0.64) | Return On Equity (17.67) |
The market value of BioXcel Therapeutics is measured differently than its book value, which is the value of BioXcel that is recorded on the company's balance sheet. Investors also form their own opinion of BioXcel Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is BioXcel Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BioXcel Therapeutics' market value can be influenced by many factors that don't directly affect BioXcel Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BioXcel Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if BioXcel Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BioXcel Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.